Effects of the central melanocortin system on feed intake, metabolic hormones and insulin action in the sheep.
Ehrhardt. Richard A RA; Giesy. Sarah L SL; Hileman. Stanley M SM; Houseknecht. Karen L KL; Boisclair. Yves R YR
Key Findings
- Central MTI infusion (0.03 nmol/h) reduced feed intake by about 40% in sheep.
- MTI increased plasma triiodothyronine (T3) and thyroxine (T4) independent of reduced food intake.
Practical Outcomes
- MTI may act as a potent appetite suppressant and boost thyroid hormone levels, which could theoretically support weight loss or higher metabolic rate. However, the same central activation may blunt insulin’s control over liver glucose output, raising a potential risk for insulin resistance. Because the study used direct brain infusion in sheep, translating these effects to human subcutaneous or nasal MTI use requires caution, and dosage/administration protocols remain unvalidated for humans.
Summary
In sheep, giving the peptide melanotan‑I directly into the brain cuts food intake, raises thyroid hormones (T3 and T4), and lowers leptin at higher feeding levels, but it also makes the liver less responsive to insulin's signal to stop making glucose. It doesn't change blood sugar, insulin, or cortisol levels.
Abstract
Voluntary feed intake is insufficient to meet the nutrient demands associated with late pregnancy in prolific ewes and early lactation in high-yielding dairy cows. Under these conditions, peripheral signals such as growth hormone and ceramides trigger adaptations aimed at preserving metabolic well-being. Recent work in rodents has shown that the central nervous system-melanocortin (CNS-MC) system, consisting of alpha-melanocyte-stimulating hormone (α-MSH) and agouti-related peptide (AGRP) acting respectively as agonist and antagonist on central MC receptors, contributes to the regulation of some of the same adaptations. To assess the effects of the CNC-MC on peripheral adaptations in ruminants, ewes were implanted with an intracerebroventricular cannula in the third ventricle and infused over days with artificial cerebrospinal fluid (aCSF), the α-MSH analog melanotan-I (MTI), or AGRP. Infusion of MTI at 0.03 nmol/h reduced intake, expressed as a fold of maintenance energy requirement (M), from 1.8 to 1.1 M (P < 0.0001), whereas AGRP at 0.3 nmol/h increased intake from 1.8 to 2.0 M (P < 0.01); these doses were used in all subsequent experiments. To assess the effect of MTI on plasma variables, sheep were fed ad libitum and infused with aCSF or MTI or pair-fed to MTI-treated sheep and infused with aCSF (aCSFPF). Feed intake of the MTI and aCSFPF groups was 40% lower than the aCSF group (P < 0.0001). MTI increased plasma triiodothyronine and thyroxine in an intake-independent manner (P < 0.05 or less) but was devoid of effects on plasma glucose, insulin, and cortisol. None of these variables were altered by AGRP infusion in sheep fed at a fixed intake of 1.6 M. To assess the effect of CNS-MC activation on insulin action, ewes were infused with aCSF or MTI over the last 3 d of a 14-d period when energy intake was limited to 0.3 M and studied under basal conditions and during hyperinsulinemic-euglycemic clamps. MTI had no effect on plasma glucose, plasma insulin, or glucose entry rate under basal conditions but blunted the ability of insulin to inhibit endogenous glucose production during hyperinsulinemic-euglycemic clamps (P < 0.0001). Finally, MTI tended to reduce plasma leptin in sheep fed at 0.3 M (P < 0.08), and this effect became significant at 0.6 M (P < 0.05); MTI had no effect on plasma adiponectin irrespective of feeding level. These data suggest a role for the CNC-MC in regulating metabolic efficiency and peripheral insulin action.
Study Information
pubmed
2023
2023-01-03T00:00:00.000Z
10.1093/jas/skad398
2